September 16, 2025 — Leads & Copy — Oncolytics Biotech Inc. (Nasdaq: ONCY) provided updates on enrollment progress, U.S. site expansion, and expected data readouts from the ongoing GOBLET trial evaluating pelareorep in gastrointestinal cancers. The study is supported in part by a grant from the Pancreatic Cancer Action Network (PanCAN).
According to Dr. Dirk Arnold, Director of Asklepios Tumorzentrum Hamburg and Primary Investigator of the GOBLET study, the GOBLET trial is designed to rigorously evaluate pelareorep’s potential across gastrointestinal cancers. Arnold noted that strong early efficacy signals give confidence that pelareorep may become a foundational immunotherapy for these difficult-to-treat tumors, and expanding enrollment into the U.S. will broaden the scope and impact of these data.
The company expects to provide an efficacy update regarding ORR in Cohort 4 in the fourth quarter of 2025 and anticipates providing a Cohort 5 interim efficacy update, including overall survival, in the first quarter of 2026.
The company recently submitted a protocol amendment to allow the GOBLET study to open U.S. clinical sites within the next few months. Upon approval, Northwestern University and other academic institutions are expected to serve as U.S. sites for GOBLET.
Jared Kelly, Chief Executive Officer of Oncolytics, said the company expects to build on this clinical momentum to lay the foundation for its regulatory strategy. Kelly added that it’s imperative to leverage clinical data to obtain regulatory clarity and position pelareorep as a platform immunotherapy in these gastrointestinal tumors where patients desperately need treatment options.
Company Contact:
Jon Patton
Director of IR & Communication
jpatton@oncolytics.ca
Investor Relations for Oncolytics:
Mike Moyer
LifeSci Advisors
+1-617-308-4306
mmoyer@lifesciadvisors.com
Media Contact for Oncolytics:
Owen Blaschak
LifeSci Communications
oblaschak@lifescicomms.com
Source: Oncolytics Biotech Inc.
